Guardant Health, Inc. (NASDAQ:GH) Receives $40.60 Consensus Target Price from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH - Get Free Report) have been assigned an average rating of "Buy" from the fifteen analysts that are covering the stock, Marketbeat Ratings reports. Fifteen analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have covered the stock in the last year is $40.60.

A number of analysts have weighed in on the stock. Leerink Partners reduced their price target on shares of Guardant Health from $60.00 to $50.00 and set an "outperform" rating for the company in a report on Thursday, October 17th. The Goldman Sachs Group increased their target price on shares of Guardant Health from $32.00 to $36.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. UBS Group raised their price objective on Guardant Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, August 21st. Finally, Sanford C. Bernstein decreased their price objective on Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a report on Wednesday, October 30th.

Insider Activity at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of the firm's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the sale, the director now directly owns 7,648 shares in the company, valued at approximately $228,675.20. This trade represents a 27.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Musa Tariq sold 2,320 shares of the stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now directly owns 2,676 shares of the company's stock, valued at $93,660. This represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,316 shares of company stock worth $171,380 in the last quarter. Corporate insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On Guardant Health

A number of large investors have recently bought and sold shares of the company. JNBA Financial Advisors bought a new position in shares of Guardant Health in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new position in Guardant Health in the third quarter valued at approximately $34,000. Quarry LP acquired a new position in shares of Guardant Health during the 2nd quarter worth approximately $44,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Guardant Health during the 2nd quarter worth approximately $71,000. Finally, Byrne Asset Management LLC acquired a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $77,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Guardant Health Stock Up 2.5 %

NASDAQ:GH traded up $0.86 during trading hours on Monday, reaching $35.62. The company's stock had a trading volume of 1,839,591 shares, compared to its average volume of 2,038,397. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. The company has a market cap of $4.40 billion, a price-to-earnings ratio of -8.40 and a beta of 1.26. Guardant Health has a one year low of $15.81 and a one year high of $38.53. The business's 50-day moving average is $28.21 and its 200-day moving average is $28.21.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The company had revenue of $191.48 million for the quarter, compared to the consensus estimate of $170.49 million. During the same period in the previous year, the company earned ($0.73) EPS. The firm's revenue for the quarter was up 33.9% compared to the same quarter last year. Equities research analysts predict that Guardant Health will post -3.44 EPS for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.